These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 15136967)

  • 1. Aldosterone and cardiovascular remodelling: focus on myocardial failure.
    Shieh FK; Kotlyar E; Sam F
    J Renin Angiotensin Aldosterone Syst; 2004 Mar; 5(1):3-13. PubMed ID: 15136967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aldosterone blockade in heart failure.
    Struthers AD
    J Renin Angiotensin Aldosterone Syst; 2004 Sep; 5 Suppl 1():S23-7. PubMed ID: 15526239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Central infusion of aldosterone synthase inhibitor attenuates left ventricular dysfunction and remodelling in rats after myocardial infarction.
    Huang BS; White RA; Ahmad M; Tan J; Jeng AY; Leenen FH
    Cardiovasc Res; 2009 Feb; 81(3):574-81. PubMed ID: 18689429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aldosterone-synthase overexpression in heart: a tool to explore aldosterone's effects.
    Heymes C; Garnier A; Fuchs S; Bendall JK; Nehme J; Ambroisine ML; Robidel E; Swynghedauw B; Milliez P; Delcayre C
    Mol Cell Endocrinol; 2004 Mar; 217(1-2):213-9. PubMed ID: 15134820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fiftieth anniversary of aldosterone: from discovery to cardiovascular therapy.
    Tan LB; Schlosshan D; Barker D
    Int J Cardiol; 2004 Sep; 96(3):321-33. PubMed ID: 15310530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistent cardiac aldosterone synthesis in angiotensin II type 1A receptor-knockout mice after myocardial infarction.
    Katada J; Meguro T; Saito H; Ohashi A; Anzai T; Ogawa S; Yoshikawa T
    Circulation; 2005 May; 111(17):2157-64. PubMed ID: 15851599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of the renin-angiotensin-aldosterone system in heart failure.
    Unger T; Li J
    J Renin Angiotensin Aldosterone Syst; 2004 Sep; 5 Suppl 1():S7-10. PubMed ID: 15526242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of cardiac remodeling after myocardial infarction in transgenic rats deficient in brain angiotensinogen.
    Lal A; Veinot JP; Ganten D; Leenen FH
    J Mol Cell Cardiol; 2005 Sep; 39(3):521-9. PubMed ID: 15950985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Critical role of CNS effects of aldosterone in cardiac remodeling post-myocardial infarction in rats.
    Lal A; Veinot JP; Leenen FH
    Cardiovasc Res; 2004 Dec; 64(3):437-47. PubMed ID: 15537497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathophysiology of heart failure following myocardial infarction.
    Struthers AD
    Heart; 2005 May; 91 Suppl 2(Suppl 2):ii14-6; discussion ii31, ii43-8. PubMed ID: 15831601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Why are mineralocorticoid receptor antagonists cardioprotective?
    Chai W; Danser AH
    Naunyn Schmiedebergs Arch Pharmacol; 2006 Dec; 374(3):153-62. PubMed ID: 17075718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eplerenone: hypertension, heart failure and the importance of mineralocorticoid receptor blockade.
    Funder JW
    Future Cardiol; 2006 Sep; 2(5):535-41. PubMed ID: 19804189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Rationale, characteristics and study design of PREAMI (Perindopril and Remodelling in the Elderly with Acute Myocardial Infraction)].
    Magrini G; Nicolosi GL; Chiariello M; Ferrari R; Remme P; Tavazzi L
    Ital Heart J; 2005 Nov; 6 Suppl 7():14S-23S. PubMed ID: 16485513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardioprotection by aldosterone receptor antagonism in heart failure. Part I. The role of aldosterone in heart failure.
    Dieterich HA; Wendt C; Saborowski F
    Fiziol Cheloveka; 2005; 31(6):97-105. PubMed ID: 16366159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential novel pharmacological therapies for myocardial remodelling.
    Landmesser U; Wollert KC; Drexler H
    Cardiovasc Res; 2009 Feb; 81(3):519-27. PubMed ID: 19019834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of aldosterone blockade for treatment of heart failure and post-acute myocardial infarction.
    Greenberg B; Zannad F; Pitt B
    Am J Cardiol; 2006 May; 97(10A):34F-40F. PubMed ID: 16698333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effects of aldosterone receptor blocker therapy on cardiac remodeling].
    Boccanelli A; Battagliese A
    G Ital Nefrol; 2006; 23 Suppl 34():S57-63. PubMed ID: 16633997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular effects of aldosterone and post-acute myocardial infarction pathophysiology.
    Cohn JN; Colucci W
    Am J Cardiol; 2006 May; 97(10A):4F-12F. PubMed ID: 16698330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hemodynamic and neurohormonal predictors and consequences of the development of atrial fibrillation in dogs with chronic heart failure.
    Tisdale JE; Borzak S; Sabbah HN; Shimoyama H; Goldstein S
    J Card Fail; 2006 Dec; 12(9):747-51. PubMed ID: 17174237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The AREA IN-CHF trial (antiremodeling effect of aldosterone receptors blockade with canrenone in mild chronic heart failure): rationale and design].
    Cacciatore G; Boccanelli A; Mureddu GF; Maggioni AP; Latini R; Masson S; de Simone G;
    Ital Heart J; 2005 May; 6 Suppl 1():66S-74S. PubMed ID: 15945301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.